Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis

• Status: Completed
• Trial end date: 2017-05-24
• Target enrollment: 0
• Participant gender: All

Summary

This two cohort study (Cohort A and B) is being conducted to assess the safety and efficacy of BBI-2000 for the prevention (Cohort A) and treatment (Cohort B) of delayed type hypersensitivity reaction.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Brickell Biotech, Inc.

Criteria

Inclusion Criteria:

• Individuals aged 18 to 65 years inclusive at the time of consent, and either female of non-reproductive potential or male.

• Subjects must be healthy, normal volunteers per physical exam, laboratory and EKG assessments

Exclusion Criteria:

• History of contact dermatitis to medical adhesive bandages or glue.

• Medical history of dermatographism.

• Any medical condition causing immunosuppression.

• Prior treatment or therapies or history of sensitivity to any of the study products.